Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merck Sharp & Dohme LLC
Age
0–17
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participant is scheduled to have surgery requiring a 48 hour (Part I) or 24 hour (Part II) hospital stay
Participant is scheduled to receive general anesthesia
Participant is scheduled to receive opioids (e.g. morphine or fentanyl)
Female participants of childbearing potential must have negative pregnancy test prior to drug administration
A female participant who is of reproductive potential must agree to remain abstinent or use a barrier form of contraception for at least 14 days prior to, throughout, and for at least one month following the last dose of study medication
Participant weighs 6 kg or more
You may not be if
Participant is undergoing surgery for a life-threatening condition
Participant is pregnant or breast feeding
Participant has vomited within 24 hours prior to surgery
Participant has a known history of QT prolongation or is currently taking other medicinal products that lead to QT prolongation
Participant has an active infection (e.g., pneumonia), congestive heart failure, bradyarrythmia, any uncontrolled disease (e.g., diabetic ketoacidosis, gastrointestinal obstruction), evidence of any clinically significant respiratory, metabolic, hepatic, renal dysfunction, or a history of any illness, including morbid obesity, that might pose unwarranted risk
Clareo Health | A Study of Aprepitant (MK-0869) in Pediatric Participants Undergoing Surgery (MK-0869-148)
